Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12080211 | 0.98 | SMN1; SMN2 (0.34) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL19230234 | 0.82 | SMN1; SMN2 (0.38) | SIGMAR1ALDH1A1SMN1; SMN2POLBCXCR4 | |
| SCHEMBL18787478 | 0.74 | GNAO1 (0.35) | SIGMAR1 | |
| SCHEMBL1104721 | 0.73 | SIGMAR1 (0.44) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL6431074 | 0.73 | SIGMAR1 (0.36) | SIGMAR1ALDH1A1HTTCHRM5CHRM3 | |
| SCHEMBL17327706 | 0.73 | GNAO1 (0.37) | SIGMAR1CXCR4 | |
| SCHEMBL14584234 | 0.72 | SIGMAR1 (0.39) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL1308918 | 0.72 | SIGMAR1 (0.43) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB | |
| Bromide SCHEMBL4936619 | 0.72 | SIGMAR1 (0.43) | SIGMAR1ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL18073766 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| EP-2448929-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001052-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | SIGMAR1 3192/4885ALDH1A1 1912/4885HTT 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.